Skip to main content

PAVmed Inc.

corporate_fare Company Profile

PAVmed Inc.

PAVmed Inc. engages in acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, including chronic heartburn and acid reflux or simply reflux in patients; and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay performed on surface esophageal cells collected with EsoCheck. Its product pipeline also comprises EsoCure Esophageal Ablation Device for treating dysplastic BE; PortIO, an implantable intraosseous vascular access device; and Veris cancer care platform. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York

Exchange: NASDAQSector: Industrial Applications And Services

show_chartPrice Chart

Loading chart...

feed PAVM - Latest Insights

PAVM
Apr 20, 2026, 9:17 PM EDT
Filing Type: S-3
Importance Score:
9
PAVM
Apr 09, 2026, 8:56 PM EDT
Filing Type: SCHEDULE 13D
Importance Score:
8
PAVM
Mar 30, 2026, 8:10 AM EDT
Filing Type: 8-K
Importance Score:
9
PAVM
Mar 30, 2026, 8:00 AM EDT
Source: Dow Jones Newswires
Importance Score:
9
PAVM
Mar 27, 2026, 5:15 PM EDT
Filing Type: 8-K
Importance Score:
9
PAVM
Mar 27, 2026, 5:08 PM EDT
Filing Type: 10-K
Importance Score:
8
PAVM
Feb 24, 2026, 4:15 PM EST
Filing Type: DEF 14A
Importance Score:
9
PAVM
Feb 13, 2026, 5:00 PM EST
Filing Type: PRE 14A
Importance Score:
9
PAVM
Feb 04, 2026, 8:12 AM EST
Filing Type: 8-K
Importance Score:
9
PAVM
Jan 23, 2026, 4:30 PM EST
Filing Type: 8-K
Importance Score:
8